Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:430460.
doi: 10.1155/2012/430460. Epub 2011 Nov 14.

Beneficial effect of ultra-low-dose aspirin in platelet activity alterations and haemorrhage observed in experimental portal hypertension

Affiliations

Beneficial effect of ultra-low-dose aspirin in platelet activity alterations and haemorrhage observed in experimental portal hypertension

F X Eizayaga et al. Thrombosis. 2012.

Abstract

Ultra-low-dose aspirin has shown a prothrombotic effect in the laser-induced thrombosis model. Several studies of our laboratory have shown a positive effect in rats with two different experimental models of portal hypertension: portal vein ligation, a model with an almost normal liver, and 30 days of bile duct ligation, a model with cirrhosis and presence of ascitis. In both models of portal hypertensive rats, bleeding time was prolonged and thrombi formation, in a laser-induced model of thrombi production, decreased. The hypotheses of the presented studies were that ultra-low-dose aspirin could decrease the bleeding complications in these models and that the mechanism for these effects could act thorough the COX pathway. In different studies, ultra-low dose of aspirin normalized the induced hemorrhage time, thrombi production, and platelet-endothelial cell interaction. The possible beneficial role of these doses of aspirin and mechanism of COX 2 inhibition are discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Laser-induced thrombus formation. Study of number of emboli (expressed in number). Control: sham-operated rats. Cont. + ULDA: sham-operated rats pretreated with ULDA. Cirrh.: cirrhotic rats. Cirrh. + ULDA: cirrhotic rats pretreated with ULDA. a,b P < 0.001 versus control (ANOVA, Bonferroni post-test).
Figure 2
Figure 2
Laser-induced thrombus formation. Study of Duration of embolisation (expressed in minutes). Control: sham-operated rats. Cont. + ULDA: sham-operated rats pretreated with ULDA. Cirrh.: cirrhotic rats. Cirrh + ULDA: cirrhotic rats pretreated with ULDA. a P < 0.05 versus control; b P < 0.01 versus control; c P < 0.05 versus cirrhosis (ANOVA, Bonferroni post-test).
Figure 3
Figure 3
Study of induced hemorrhagic time (expressed in seconds). Control: Sham operated rats. Cont + ULDA: Sham-operated rats pretreated with ULDA. Cirrh.: Cirrhotic rats. Cirrh. + ULDA: Cirrhotic rats pretreated with ULDA. a P < 0.05 versus Control. (ANOVA, Bonferroni post-test).
Figure 4
Figure 4
Study of platelet count (expressed in number × 103). Control: sham-operated rats. Cont + ULDA: Sham-operated rats pretreated with ULDA. Cirrh.: cirrhotic rats. Cirrh. + ULDA: cirrhotic rats pretreated with ULDA.
Figure 5
Figure 5
Study of Hematocrit (expressed in %): Control: Sham operated rats. Cont + ULDA: Sham operated rats pretreated with ULDA. Cirrh: Cirrhotic rats. Cirrh + ULDA: Cirrhotic rats pretreated with ULDA. a P < 0.01 versus Control. (ANOVA, Bonferroni post-test).

References

    1. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. New England Journal of Medicine. 2010;362(9):823–832. - PubMed
    1. Lisman T, Leebeek FW, de Groot PG. Haemostatic abnormalities in patients with liver disease. Journal of Hepatology. 2002;37(2):280–287. - PubMed
    1. Thomas DP, Ream VJ, Stuart RK. Platelet aggregation in patients with Laennec’s cirrhosis of the liver. New England Journal of Medicine. 1967;276(24):1344–1348. - PubMed
    1. Thomas DP. Abnormalities of platelet aggregation in patients with alcoholic cirrhosis. Annals of the New York Academy of Sciences. 1972;201:243–250. - PubMed
    1. Ordinas A, Maragall S, Castillo R, Nurden AT. A glycoprotein I defect in the platelets of three patients with severe cirrhosis of the liver. Thrombosis Research. 1978;13(2):297–302. - PubMed